OBJECTIVETo investigate the mechanism of miR-133a in reversing neonatal rat cardiomyocyte hypertrophy induced by phenylephrine.

METHODSA miR-133a precursor cDNA was used to construct an adenovirus vector, which was transfected into 293 cells to harvest miR-133a-containing virus. Neonatal rat cardiac myocytes treated by phenylephrine were exposed to miR-133a adenovirus, and the changes in cell area was measured; the expression levels of miR-133a and Acta1, Actc1, Actb, Myh6, Myh7, and BNP mRNAs were detected by quantitative RT-PCR.

RESULTSPhenylephrine treatment increased the area of cardiomyocytes by more than 3 folds and significantly enhanced the expression levels of Acta1, Actc1, Actb, Myh6, Myh7 and BNP mRNAs. All these changes were obviously reverse by miR-133a treatment.

CONCLUSIONmiR-133a is an important regulator of phenylephrine-induced cardiomyocyte hypertrophy and negatively regulates this process.

Adenoviridae ; Animals ; Cells, Cultured ; Genetic Vectors ; Hypertrophy ; MicroRNAs ; genetics ; Myocytes, Cardiac ; cytology ; pathology ; Phenylephrine ; adverse effects ; RNA, Messenger ; Rats ; Transfection

Objective To retrospectively analyze the clinical characteristics of patients with malignant tumors combined with new coronavirus pneumonia (COVID-19), and to provide a scientific basis for clinical treatment. Methods SPSS 20.0 was used for data analysis. The t-test was used for quantitative data, and chi-square test/Fisher-exact test was used for qualitative data. Binary logistic regression was used for multivariate analysis, and the correlation coefficient was used for multicollinearity test before regression analysis. Results A total of 61 COVID-19 infected cancer patients were included in this study. Their average age was 62.2±12.12. The most common admission symptoms were fever (54.1%), fatigue (39.3%), and cough (37.7%). The rate of the patients with severe COVID-19 was 54.1%. Having 3 or more complications (OR: 2.07, 95%CI: 3.14-2698.12), fever (OR: 12.22, 95%CI: 1.20-86.70), low percentage of lymphocytes (OR: 15.56, 95%CI: 1.78-136.24) and low serum albumin level (OR: 254.64, 95%CI: 8.56-7576.41) were risk factors for COVID-19 severity. The fatality rate of the subjects was 8.2%, and the average hospital stay was 26.7±19.69 days. Furthermore, the severity of COVID-19 had a statistically significant impact on the average hospital stay (t=-3.48, P<0.01). Conclusion Patients with malignant tumors combined with COVID-19 have a higher severity rate, fatality rate, and average hospital stay than ordinary COVID-19 patients. Underlying diseases, fever, low lymphocyte percentage, and low serum albumin levels are the factors for the increase of the illness severity in patients with malignant tumors combined with COVID-19.